Author:
Fink Thomas H.,Huber Rudolf M.,Heigener David F.,Eschbach Corrina,Waller Cornelius,Steinhauer Ernst U.,Virchow Johann C.,Eberhardt Frank,Schweisfurth Hans,Schroeder Michael,Ittel Thomas,Hummler Simone,Banik Norbert,Bogenrieder Thomas,Acker Thomas,Wolf Martin
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference15 articles.
1. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up;Sundstrøm;J Clin Oncol,2002
2. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer;Eckardt;J Clin Oncol,2006
3. A multicentre randomised phase II study of oral topotecan versus IV topotecan for second line therapy in sensitive patients with small cell lung cancer;Pawel;Proc Am Soc Clin Oncol,1999
4. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;Pawel;J Clin Oncol,1999
5. An Eastern Cooperative Oncology Group phase II study of topotecan in extensive stage small cell lung cancer;Schiller;Ann Oncol,1996
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献